CAR T-Cell Therapy Consults: Navigating a New Landscape

This case-based module will introduce CAR T-cell therapy and review patient cases in MM, B-ALL, and BCL/DLBCL. This activity will help you identify appropriate patients for CAR T-cell therapy and cover the toxicities associated with this treatment. 

Activity Title

CAR T-Cell Therapy Consults: Navigating a New Landscape

Topic

CAR T-Cell Therapy

Accreditation Type

Physicians—maximum of 1.50 AMA PRA Category 1 Credit(s)™ and 1.50 ABIM MOC points

Accreditor

American Society of Hematology

Release Date

9/26/2022

Expiration Date

9/25/2023

Estimated Time to Complete Activity

90 minutes

TARGET AUDIENCE
This educational activity is intended for hematologists, oncologists, and other healthcare team members involved in the treatment of patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and B-cell lymphoma/diffuse large B-cell lymphoma.

PROGRAM OVERVIEW
This case-based module will introduce CAR T-cell therapy and review patient cases in MM, B-ALL, and BCL/DLBCL. This activity will help you identify appropriate patients for CAR T-cell therapy and cover the toxicities associated with this treatment.

LEARNING OBJECTIVES
Upon completion of this course, the learners should be able to:
  • Summarize key aspects of approved or emerging CAR T-cell therapies for use in MM, B-ALL, and BCL/DLBCL, including development, mechanism, specific indications, and serious adverse events
  • Select patients who might be appropriate for CAR T-cell therapy 
  • Complete timely and informative referrals to CAR T-cell therapy specialty centers
  • Create a plan that reflects issues to be monitored and addressed post-CAR T-cell therapy in the short- and long-term

PLANNING COMMITTEE
Caitlin Costello, MD 
Associate Professor of Medicine
UC San Diego Health

Catherine Lee, MD
Associate Professor, Internal Medicine
Huntsman Cancer Center, University of Utah

Heidi Thompson, PhD
Medical Director
The France Foundation

FACULTY 
Caitlin Costello, MD 
Associate Professor of Medicine
UC San Diego Health

Catherine Lee, MD
Associate Professor, Internal Medicine
Huntsman Cancer Center, University of Utah

INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
Technical Requirements: http://www.francefoundation.com/general-requirements.html
Credit fulfillment: If you are requesting AMA credit, or a certificate of participation, your certificate will be available for download 

ACCREDITED PROVIDER 
This activity has planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Transplantation and Cellular Therapy (ASCT) and the France Foundation. The American Society of Hematology (ASH) is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION
The American Society of Hematology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals completing this course will be issued a statement of participation.

Maintenance of Certification  
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 ABIM MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the American Society of Hematology (ASH) and Collaborating Partners (TFF and ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. ASH, TFF, and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, ASH, TFF, and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ASH, TFF, and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

 

Name of Individual

 Role in Activity

Name of Commercial Interest(s)

Nature of Relationship(s)

Mechanism(s) implemented to resolve conflict of interest

Caitlin Costello, MD

Planning Committee Member, Faculty

  • Bristol Myers Squibb
  • Janssen
  • Pfizer
  • Takeda
  • Non-CE Consultant, Contract Research
  • Non-CE Consultant, Contract Research
  • Non-CE Consultant
  • Non-CE Consultant, Contract Research

All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member

 

Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning

Catherine Lee, MD 

Planning Committee Member, Faculty

  • Bristol Myers Squibb
  • Frensenius Kabi
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Kadmon Corporation
  • Kite Pharma
  • McGraw-Hill
  • Non-CE Consultant
  • Non-CE Consultant
  • Non-CE Consultant, Contract Research
  • Non-CE Consultant
  • Non-CE Consultant
  • Non-CE Consultant
  • Royalty

 

All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member

 

Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning

Erika Fox

TFF Staff

NA

NA

NA

Heidi Thompson, PhD 

Planning Committee Member, Content Reviewer

NA

NA

NA

Disclosure of Unlabeled Use:
ASH, TFF, and ASTCT requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. There is no discussion of off label products or procedures in this activity. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ASH, TFF, and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by educational grants from CRISPR Therapeutics, Janssen, Kite Pharma, and Novartis.

Disclaimer
ASH, TFF, and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASH, TFF, and ASTCT and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2022 The American Society of Hematology. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 

  • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered. 
  • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The American Society of Hematology’s prior written permission 

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy. 

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.


Key:

Complete
Failed
Available
Locked
CAR T-Cell Therapy Consults: Navigating a New Landscape
Begin self-paced component package.
Begin self-paced component package.